Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

Executive Summary

When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.

Advertisement

Related Content

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
French Patients To Get Pre-Approval Access To Bayer’s Vitravki
Q4 Preview: How Will Bayer Survive Patent Cliff?
Lilly/Loxo Deal Came Together Quickly
Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel